Ownership and insider activity for OnKure Therapeutics, Inc. (OKUR): insider transactions, US Senate and House trading disclosures and shares outstanding. Track how corporate insiders and politicians are trading the stock.
OnKure, Inc., established in 2011 and based in Boulder, Colorado, operates as a biopharmaceutical company primarily engaged in the creation and advancement of precise therapeutic agents for cancer. A core area of their research centers on developing highly selective inhibitors for histone deacetylases.
Price
| Price | $2.88 |
| Market Cap | $117M |
| Exchange | NASDAQ |
| Country | US |
Recent Insider Transactions
| Date | Insider | Type | Shares | Value |
|---|---|---|---|---|
| 2026-08-07 | Manke Isaac | |||
| 2026-08-07 | Mathers Edward T | A-Award | 22,350 | $93K |
| 2026-08-07 | Ratcliffe Liam | A-Award | 22,350 | $93K |
| 2026-08-07 | Phillips Andrew John | A-Award | 22,350 | $93K |
| 2026-08-07 | Manke Isaac | A-Award | 300,000 | $1.2M |
| 2026-08-07 | Manke Isaac | A-Award | 15,300 | $63K |
| 2026-08-07 | Manke Isaac | D-Return | 15,300 | $278K |
| 2026-08-07 | Jansen Valerie Malyvanh | A-Award | 22,350 | $93K |
| 2026-08-07 | GREY MICHAEL G | A-Award | 22,350 | $93K |
| 2026-08-07 | Carruthers R Michael | A-Award | 22,350 | $93K |
Balance Sheet (10y)
| Year | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $53.6M | $124.7M | $11.5M | $29.9M | $110.8M | $59.0M |
| Short-term Investments | 0 | $23.0M | 0 | 0 | 0 | 0 |
| Receivables | 0 | 0 | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Current Assets | $55.0M | $153.7M | $13.6M | $33.8M | $113.0M | $60.8M |
| Property, Plant & Equipment | $69000 | $212000 | $2.0M | $1.9M | $1.8M | $1.0M |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Assets | $55.2M | $154.0M | $16.0M | $35.7M | $114.9M | $62.1M |
| Accounts Payable | 0 | 0 | $2.5M | $3.4M | $3.0M | $1.4M |
| Short-term Debt | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Current Liabilities | $4.6M | $6.2M | $5.5M | $7.3M | $10.5M | $5.9M |
| Long-term Debt | $92.7M | 0 | 0 | 0 | 0 | 0 |
| Total Liabilities | $97.3M | $6.8M | $70.4M | $137.6M | $11.1M | $5.9M |
| Retained Earnings | -$45.0M | -$84.7M | -$57.1M | -$102.1M | -$154.7M | -$214.2M |
| Total Equity | -$42.1M | $147.2M | -$54.4M | -$101.8M | $103.8M | $56.2M |
| Total Debt | $92.7M | 0 | $637000 | $674000 | $1.1M | $549000 |
| Net Debt | $39.1M | -$147.7M | -$10.9M | -$29.2M | -$109.7M | -$58.5M |
| Working Capital | $50.4M | $147.5M | $8.1M | $26.5M | $102.5M | $54.9M |
Financial Health
| Debt / Equity | 0.01 |
| Current Ratio | 26.75 |
| Piotroski F-Score | 1 |
| Altman Z-Score | -3.15 |
Profitability
| Return on Equity | -49.02% |
| Return on Invested Capital | -35.91% |
| Return on Assets | -32.73% |
| Gross Margin | 0.00% |
| Operating Margin | 0.00% |
| Net Margin | 0.00% |
Related companies: ALGS · ATNM · BRNS · CVM · FGEN · KZR · MRSN
Explore sector: Healthcare · Biotechnology
More sections of OKUR: Overview · Financials · Valuation · Statistics · Estimates · Technical · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks